Exelixis Inc
EXEL41.415USD
+0.535+1.31%
Market hours （ET）Quotes delayed by 15 min
11.10BMarket Cap
16.84P/E TTM
More Details of Exelixis Inc Company
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Exelixis Inc Info
Ticker SymbolEXEL
Company nameExelixis Inc
IPO dateApr 11, 2000
CEOMorrissey (Michael M)
Number of employees1147
Security typeOrdinary Share
Fiscal year-endApr 11
Address1851 Harbor Bay Parkway
CityALAMEDA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94502
Phone16508377000
Websitehttps://www.exelixis.com/
Ticker SymbolEXEL
IPO dateApr 11, 2000
CEOMorrissey (Michael M)
Company Executives of Exelixis Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.17M
-4.48%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.17M
-7.87%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President
Executive Vice President
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
220.48K
-14.72%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
159.99K
+6.53%
Dr. Brenda Hefti, J.D., Ph.D.
Dr. Brenda Hefti, J.D., Ph.D.
General Counsel
General Counsel
120.61K
+33.36%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
81.98K
+13.60%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
10.57K
+1285.98%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.17M
-4.48%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.17M
-7.87%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President
Executive Vice President
410.70K
-12.57%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Research and Development
Executive Vice President - Research and Development
359.32K
-8.22%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
340.04K
-2.17%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
220.48K
-14.72%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
CABOMETYX
517.89M
91.14%
License revenues
49.30M
8.68%
COMETRIQ
2.12M
0.37%
Collaboration services revenues
-1.05M
-0.19%
By RegionUSD
Name
Revenue
Proportion
U.S
524.77M
92.35%
Europe
37.03M
6.52%
Japan
6.46M
1.14%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
CABOMETYX
517.89M
91.14%
License revenues
49.30M
8.68%
COMETRIQ
2.12M
0.37%
Collaboration services revenues
-1.05M
-0.19%
Shareholding Stats
Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.70%
BlackRock Institutional Trust Company, N.A.
9.33%
Farallon Capital Management, L.L.C.
7.27%
Renaissance Technologies LLC
5.77%
State Street Investment Management (US)
4.15%
Other
63.79%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.70%
BlackRock Institutional Trust Company, N.A.
9.33%
Farallon Capital Management, L.L.C.
7.27%
Renaissance Technologies LLC
5.77%
State Street Investment Management (US)
4.15%
Other
63.79%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.91%
Investment Advisor/Hedge Fund
30.97%
Hedge Fund
15.65%
Pension Fund
3.02%
Individual Investor
2.18%
Research Firm
2.01%
Sovereign Wealth Fund
1.26%
Bank and Trust
0.61%
Family Office
0.19%
Other
0.21%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1065
260.68M
98.50%
--
2025Q3
1092
260.70M
99.86%
-131.97K
2025Q2
1104
260.91M
98.66%
+4.64M
2025Q1
1034
261.04M
99.05%
-11.93M
2024Q4
973
257.78M
94.19%
+2.55M
2024Q3
898
254.99M
92.51%
+5.22M
2024Q2
882
250.15M
93.36%
-9.07M
2024Q1
880
259.43M
91.82%
-18.97M
2023Q4
863
265.17M
90.49%
-5.75M
2023Q3
825
271.59M
91.03%
-8.20M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
27.41M
10.18%
-1.20M
-4.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
25.44M
9.45%
-1.05M
-3.97%
Jun 30, 2025
Farallon Capital Management, L.L.C.
16.04M
5.96%
-2.60M
-13.95%
Jun 30, 2025
Renaissance Technologies LLC
15.82M
5.88%
+995.50K
+6.72%
Jun 30, 2025
State Street Investment Management (US)
11.38M
4.23%
-404.95K
-3.43%
Jun 30, 2025
AQR Capital Management, LLC
7.61M
2.83%
+712.19K
+10.33%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
8.78M
3.26%
+980.50K
+12.58%
Jun 30, 2025
LSV Asset Management
7.82M
2.9%
-340.89K
-4.18%
Jun 30, 2025
Geode Capital Management, L.L.C.
7.45M
2.77%
+28.29K
+0.38%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
5.26M
1.95%
+1.58M
+42.93%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
First Trust NYSE Arca Biotechnology Index Fund
3.41%
iShares Genomics Immunology and Healthcare ETF
3.38%
Tema Oncology ETF
3.13%
ERShares Entrepreneurs ETF
2.68%
Invesco Biotechnology & Genome ETF
2.68%
AAM Sawgrass US Large Cap Quality Growth ETF
2.59%
Alger Russell Innovation ETF
2.12%
State Street SPDR S&P Biotech ETF
2.02%
Inspire Growth ETF
1.92%
Invesco S&P MidCap Quality ETF
1.89%
View more
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.41%
iShares Genomics Immunology and Healthcare ETF
Proportion3.38%
Tema Oncology ETF
Proportion3.13%
ERShares Entrepreneurs ETF
Proportion2.68%
Invesco Biotechnology & Genome ETF
Proportion2.68%
AAM Sawgrass US Large Cap Quality Growth ETF
Proportion2.59%
Alger Russell Innovation ETF
Proportion2.12%
State Street SPDR S&P Biotech ETF
Proportion2.02%
Inspire Growth ETF
Proportion1.92%
Invesco S&P MidCap Quality ETF
Proportion1.89%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Exelixis Inc?
The top five shareholders of Exelixis Inc are:
The Vanguard Group, Inc. holds 27.41M shares, accounting for 10.18% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 25.44M shares, accounting for 9.45% of the total shares.
Farallon Capital Management, L.L.C. holds 16.04M shares, accounting for 5.96% of the total shares.
Renaissance Technologies LLC holds 15.82M shares, accounting for 5.88% of the total shares.
State Street Investment Management (US) holds 11.38M shares, accounting for 4.23% of the total shares.
The Vanguard Group, Inc. holds 27.41M shares, accounting for 10.18% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 25.44M shares, accounting for 9.45% of the total shares.
Farallon Capital Management, L.L.C. holds 16.04M shares, accounting for 5.96% of the total shares.
Renaissance Technologies LLC holds 15.82M shares, accounting for 5.88% of the total shares.
State Street Investment Management (US) holds 11.38M shares, accounting for 4.23% of the total shares.
What are the top three shareholder types of Exelixis Inc?
The top three shareholder types of Exelixis Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
How many institutions hold shares of Exelixis Inc (EXEL)?
As of 2025Q4, 1065 institutions hold shares of Exelixis Inc, with a combined market value of approximately 260.68M, accounting for 98.50% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.36%.
What is the biggest source of revenue for Exelixis Inc?
In FY2025Q2, the CABOMETYX business generated the highest revenue for Exelixis Inc, amounting to 517.89M and accounting for 91.14% of total revenue.
